Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-011152
Filing Date
2025-08-12
Accepted
2025-08-12 08:10:56
Documents
44
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q apre-20250630x10q.htm   iXBRL 10-Q 1485885
2 EX-31.1 apre-20250630xex31d1.htm EX-31.1 10379
3 EX-31.2 apre-20250630xex31d2.htm EX-31.2 10665
4 EX-32.1 apre-20250630xex32d1.htm EX-32.1 6417
5 EX-32.2 apre-20250630xex32d2.htm EX-32.2 6840
  Complete submission text file 0001558370-25-011152.txt   4034505

Data Files

Seq Description Document Type Size
6 EX-101.SCH apre-20250630.xsd EX-101.SCH 26236
7 EX-101.CAL apre-20250630_cal.xml EX-101.CAL 28254
8 EX-101.DEF apre-20250630_def.xml EX-101.DEF 98272
9 EX-101.LAB apre-20250630_lab.xml EX-101.LAB 237405
10 EX-101.PRE apre-20250630_pre.xml EX-101.PRE 163811
47 EXTRACTED XBRL INSTANCE DOCUMENT apre-20250630x10q_htm.xml XML 316842
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 215-948-4119
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39069 | Film No.: 251204142
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)